Hyperhaemolysis Syndrome: A Review of Cases

Muhammad Amirfarhan Zainudin; Asral Wirda Ahmad Asnawi*

Muhammad Amirfarhan Zainudin and Asral Wirda Ahmad Asnawi*

Volume3-Issue8
Dates: Received: 2022-08-02 | Accepted: 2022-08-05 | Published: 2022-08-12
Pages: 908-914

Abstract

Hyperhaemolysis is characterized by a haemolytic transfusion reaction that leads to life-threatening anaemia. It is usually suspected when there is a drop in haemoglobin level at least 24 hours after receiving allogeneic red cell transfusion. Decreasing haematocrit level, failure to respond to repeated RBC transfusions, markedly elevated LDH, absent haptoglobin, and gross haemoglobinuria are all suggestive of a haemolytic process. The aim of this review is to summarize and evaluate the cases from published literature to determine the features, management and outcome of reported cases of hyperhaemolysis syndrome.

FullText HTML FullText PDF DOI: 10.37871/jbres1531

Certificate of Publication

Copyright

How to cite this article

Zainudin MA, Ahmad Asnawi AW. Hyperhaemolysis Syndrome: A Review of Cases. J Biomed Res Environ Sci. 2022 Aug 12; 3(8): 908-914. doi: 10.37871/jbres1531, Article ID: JBRES1531, Available at: https://www.jelsciences.com/articles/jbres1531.pdf

Subject area(s)

Hematology

Blood Disorders

References

Menakuru SR, Priscu A, Dhillon V, Salih A. Acute Hyperhemolysis Syndrome in a Patient with Known Sickle Cell Anemia Refractory to Steroids and IVIG Treated with Tocilizumab and Erythropoietin: A Case Report and Review of Literature. Hematology Reports. 2022;14(3):235-39
Grainger JD, Makar Y, McManus A, Wynn R. Refractory hyperhaemolysis in a patient with beta-thalassaemia major. Transfus Med. 2001 Feb;11(1):55-7. doi: 10.1046/j.1365-3148.2001.00278.x. PMID: 11328573.
Wu Y, Ji Y, Dai B, Guo F, Wu Y, He Z, Mo C, Wu S, Hu Y. A case of hyperhaemolysis syndrome in a pregnant Chinese woman with β-thalassemia during perinatal transfusion. Transfus Med. 2021 Feb;31(1):24-29. doi: 10.1111/tme.12748. Epub 2020 Dec 16. PMID: 33331032.
Aragona E, Kelly M, Md MPH. Hyperhemolysis in Sickle Cell Disease. J Pediatr Hematol Oncol. 2014;36(1):e54-e56. doi: 10.1097/MPH.0b013e31828e529f.
Asnawi AW, Sathar J, Mohamed R, Deraman R, Kumaran S, Hamid SS, Zakaria MZ. Fatal Delayed Haemolytic Transfusion Reaction and Hyperhaemolysis Syndrome in a Pregnant Woman with Sickle Cell Anaemia. Indian J Hematol Blood Transfus. 2016 Jun;32(Suppl 1):251-3. doi: 10.1007/s12288-014-0495-9. Epub 2015 Jan 1. PMID: 27408406; PMCID: PMC4925481.
Boonyasampant M, Weitz IC, Kay B, Boonchalermvichian C, Liebman HA, Shulman IA. Life-threatening delayed hyperhemolytic transfusion reaction in a patient with sickle cell disease: effective treatment with eculizumab followed by rituximab. Transfusion. 2015 Oct;55(10):2398-403. doi: 10.1111/trf.13144. Epub 2015 May 18. PMID: 25989361.
Chinchilla Langeber S, Osuna Marco MP, Benedit M, Cervera Bravo Á. When a transfusion in an emergency service is not really urgent: hyperhaemolysis syndrome in a child with sickle cell disease. BMJ Case Rep. 2018 Mar 27;2018:bcr2017223209. doi: 10.1136/bcr-2017-223209. PMID: 29588281; PMCID: PMC5878350.
Dean CL, Maier CL, Roback JD, Stowell SR. Multiple hemolytic transfusion reactions misinterpreted as severe vaso-occlusive crisis in a patient with sickle cell disease. Transfusion. 2019 Feb;59(2):448-453. doi: 10.1111/trf.15010. Epub 2018 Nov 9. PMID: 30412270.
Eberly LA, Osman D, Collins NP. Hyperhemolysis Syndrome without Underlying Hematologic Disease. Case Rep Hematol. 2015;2015:180526. doi: 10.1155/2015/180526. Epub 2015 Feb 17. PMID: 25785210; PMCID: PMC4346688.
Hawke A, Conroy H, Geoghegan R, McMahon C. Erythropoietin as a treatment modality in hyperhaemolysis complicating sickle cell anaemia: GP44. Arch Dis Child. 2019;104:A47 doi: 10.1136/archdischild-2019-epa.110
Ibanez C, Habibi A, Mekontso-Dessap A, Chadebech P, Chami B, Bierling P, Galactéros F, Rieux C, Nataf J, Bartolucci P, Peyrard T, Pirenne F. Anti-HI can cause a severe delayed hemolytic transfusion reaction with hyperhemolysis in sickle cell disease patients. Transfusion. 2016 Jul;56(7):1828-33. doi: 10.1111/trf.13611. Epub 2016 May 3. PMID: 27145018.
Lee LE, Beeler BW, Graham BC, Cap AP, Win N, Chen F. Posttransfusion hyperhemolysis is arrested by targeting macrophage activation with novel use of Tocilizumab. Transfusion. 2020 Jan;60(1):30-35. doi: 10.1111/trf.15562. Epub 2019 Oct 23. PMID: 31642065.
Unnikrishnan A, Pelletier JPR, Bari S, Zumberg M, Shahmohamadi A, Spiess BD, Michael MJ, Harris N, Harrell D, Mandernach MW. Anti-N and anti-Doa immunoglobulin G alloantibody-mediated delayed hemolytic transfusion reaction with hyperhemolysis in sickle cell disease treated with eculizumab and HBOC-201: case report and review of the literature. Transfusion. 2019 Jun;59(6):1907-1910. doi: 10.1111/trf.15198. Epub 2019 Feb 15. PMID: 30768787.
Bachmeyer C, Maury J, Parrot A, Bachir D, Stankovic K, Girot R, Lionnet F. Rituximab as an effective treatment of hyperhemolysis syndrome in sickle cell anemia. Am J Hematol. 2010 Jan;85(1):91-2. doi: 10.1002/ajh.21578. PMID: 20029943.
Bezirgiannidou Z, Christoforidou A, Kontekaki E, Anastasiadis AG, Papamichos SI, Menexidou H, Margaritis D, Martinis G, Mantadakis E. Hyperhemolytic Syndrome Complicating a Delayed Hemolytic Transfusion Reaction due to anti-P1 Alloimmunization, in a Pregnant Woman with HbO-Arab/β-Thalassemia. Mediterr J Hematol Infect Dis. 2016 Oct 18;8(1):e2016053. doi: 10.4084/MJHID.2016.053. PMID: 27872733; PMCID: PMC5111518.
Cid J, Fernández J, Palomo M, Blasco M, Bailó N, Diaz-Ricart M, Lozano M. Hyperhemolytic Transfusion Reaction in Non-Hemoglobinopathy Patients and Terminal Complement Pathway Activation: Case Series and Review of the Literature. Transfus Med Rev. 2020 Jul;34(3):172-177. doi: 10.1016/j.tmrv.2020.06.002. Epub 2020 Jun 27. PMID: 32703665.
Cullis JO, Win N, Dudley JM, Kaye T. Post-transfusion hyperhaemolysis in a patient with sickle cell disease: use of steroids and intravenous immunoglobulin to prevent further red cell destruction. Vox Sang. 1995;69(4):355-7. doi: 10.1111/j.1423-0410.1995.tb00373.x. PMID: 8751307.
Danaee A, Howard J, Robertson B, Robinson S. Hyperhaemolysis in a patient with HbH disease. Transfus Med. 2014 Aug;24(4):244-5. doi: 10.1111/tme.12131. Epub 2014 Jun 23. PMID: 24957792.
Danaee A, Inusa B, Howard J, Robinson S. Hyperhemolysis in Patients With Hemoglobinopathies: A Single-Center Experience and Review of the Literature. Transfus Med Rev. 2015 Oct;29(4):220-30. doi: 10.1016/j.tmrv.2015.06.001. Epub 2015 Jun 19. PMID: 26209603.
Darabi K, Dzik S. Hyperhemolysis syndrome in anemia of chronic disease. Transfusion. 2005 Dec;45(12):1930-3. doi: 10.1111/j.1537-2995.2005.00608.x. PMID: 16371046.
Epstein SS, Hadley TJ. Successful management of the potentially fatal hyperhaemolysis syndrome of sickle cell anaemia with a regimen including bortezomib and Hemopure. J Clin Pharm Ther. 2019 Oct;44(5):815-818. doi: 10.1111/jcpt.12998. Epub 2019 Jun 25. PMID: 31237703.
Ghildyal A, Alattia L, Ong M. Hyperhemolysis in a Case of Sickle Cell Anemia: 361. Am J Clin Pathol. 2018;149:S157 doi: 10.1093/ajcp/aqx131.360
Gouveia ME, Soares NB, Santoro MS, de Azevedo FCM. Hyperhemolysis syndrome in a patient with sickle cell anemia: Case report. Revista Brasileira de Hematologia e Hemoterapia. 2015;37(4):266-68 doi: 10.1016/j.bjhh.2015.03.005
Gupta S, Fenves A, Nance S, Sykes D, Dzik W. Hyperhemolysis syndrome in a patient without a hemoglobinopathy, unresponsive to treatment with eculizumab. Transfusion. 2015;55(3):623-28. doi: 10.1111/trf.12876
Dubois EA, Cohen AF. Eculizumab. British journal of clinical pharmacology. 2009;68(3):318.